Analysis
Attovia Therapeutics priced an upsized initial public offering at $17.00 a share, raising $289.0 million in gross proceeds, and climbed 29% on its Nasdaq debut to open at $21.00 -- a market capitalization of roughly $904 million -- according to Bloomberg and GlobeNewswire. Shares began trading August 5 under the ticker ATTO on the Nasdaq Global Market.
What changed since Pulse first covered Attovia's IPO terms: the company originally set terms around a $200 million raise; by pricing day, demand pushed the deal to $289 million, a roughly 45% upsize. Goldman Sachs-backed Attovia develops therapies for immune-mediated diseases, and its debut lands in the same cluster of biotech offerings -- alongside BlossomHill, Braveheart Bio and Latigo Biotherapeutics -- that Pulse has tracked pricing above or near the top of their ranges through late July and early August.
Attovia's 29% pop is now among the strongest of that cluster, ahead of BlossomHill's more modest debut and roughly in line with Latigo's 17% first-day gain on a larger deal. The pattern across four consecutive biotech IPOs pricing well is the more durable signal than any single company's pop -- it suggests generalist and specialist biotech investors both have real capital to deploy right now, not just enough for one or two marquee names.
